Cargando…
Clinical Trial in a Dish: Personalized Stem Cell–Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT‐Prolonging Drugs
Induced pluripotent stem cells (iPSCs) have shown promise in investigating donor‐specific phenotypes and pathologies. The iPSC‐derived cardiomyocytes (iPSC‐CMs) could potentially be utilized in personalized cardiotoxicity studies, assessing individual proarrhythmic risk. However, it is unclear how c...
Autores principales: | Blinova, Ksenia, Schocken, Derek, Patel, Dakshesh, Daluwatte, Chathuri, Vicente, Jose, Wu, Joseph C., Strauss, David G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853144/ https://www.ncbi.nlm.nih.gov/pubmed/31328865 http://dx.doi.org/10.1111/cts.12674 |
Ejemplares similares
-
Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block
por: Tran, Phu N., et al.
Publicado: (2020) -
“Thorough QT/QTc in a Dish”: Can Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Predict Thorough QT Outcomes?
por: Vargas, Hugo M.
Publicado: (2019) -
QT prolongation in the STREAM Stage 1 Trial
por: Hughes, G., et al.
Publicado: (2022) -
Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs)
por: Narkar, Akshay, et al.
Publicado: (2022) -
Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer
por: Rowe, Elizabeth J., et al.
Publicado: (2022)